NL8402902A - In pyridine oplosbaar extrakt - geraffineerd ontgift endotoxinesamenstelling en gebruik ervan. - Google Patents

In pyridine oplosbaar extrakt - geraffineerd ontgift endotoxinesamenstelling en gebruik ervan. Download PDF

Info

Publication number
NL8402902A
NL8402902A NL8402902A NL8402902A NL8402902A NL 8402902 A NL8402902 A NL 8402902A NL 8402902 A NL8402902 A NL 8402902A NL 8402902 A NL8402902 A NL 8402902A NL 8402902 A NL8402902 A NL 8402902A
Authority
NL
Netherlands
Prior art keywords
preparation according
extract
amount
micrograms
refined
Prior art date
Application number
NL8402902A
Other languages
English (en)
Dutch (nl)
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of NL8402902A publication Critical patent/NL8402902A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL8402902A 1983-09-23 1984-09-21 In pyridine oplosbaar extrakt - geraffineerd ontgift endotoxinesamenstelling en gebruik ervan. NL8402902A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use
US53503783 1983-09-23

Publications (1)

Publication Number Publication Date
NL8402902A true NL8402902A (nl) 1985-04-16

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8402902A NL8402902A (nl) 1983-09-23 1984-09-21 In pyridine oplosbaar extrakt - geraffineerd ontgift endotoxinesamenstelling en gebruik ervan.

Country Status (23)

Country Link
US (1) US4663306A (de)
JP (1) JPS60120817A (de)
KR (1) KR870000843B1 (de)
AT (1) AT385659B (de)
AU (1) AU566234B2 (de)
BE (1) BE900650A (de)
CA (1) CA1244765A (de)
CH (1) CH664897A5 (de)
DE (1) DE3434766C2 (de)
DK (1) DK446684A (de)
ES (1) ES8608872A1 (de)
FI (1) FI843716L (de)
FR (1) FR2552326B1 (de)
GB (1) GB2149301B (de)
HU (1) HU192585B (de)
IL (1) IL73034A (de)
IN (1) IN157240B (de)
IT (1) IT1179444B (de)
NL (1) NL8402902A (de)
NO (1) NO843776L (de)
NZ (1) NZ209635A (de)
SE (1) SE8404707L (de)
ZA (1) ZA847405B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
CA2170142C (en) * 1993-08-27 2010-05-25 Jose M. Wade Composition and method for stimulation of reproductive performance
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
ATE227996T1 (de) 1997-08-05 2002-12-15 Bioniche Life Sciences Inc Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
US7534443B1 (en) 1998-07-16 2009-05-19 Ichiro Azuma Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
ES2340807T3 (es) * 1999-12-13 2010-06-09 Bioniche Life Sciences Inc. Oligonucleotidos sinteticos utiles terapeuticamente.
EP1250152B1 (de) * 1999-12-28 2013-05-15 Bioniche Urology IP Inc. Hyaluronsäure enthaltende synergistische Zusammensetzung zur Krebsbehandlung
PL360839A1 (en) * 2000-07-11 2004-09-20 Bayer Aktiengesellschaft Use of strains of the parapox ovis virus against organ fibrosis
US20050106155A1 (en) * 2002-03-05 2005-05-19 Tadao Ohno Solidified tissue immuoadjuvant
EP1547607A4 (de) * 2002-08-02 2008-11-26 Dainippon Sumitomo Pharma Co Herstellung einer komponente des bakterienzellwand-skeletts
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
AU2003261624A1 (en) * 2003-09-05 2005-03-29 Shenyang Sunbellcom Bio-Pharmaceutical Co., Ltd. A red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
EP1741438A4 (de) * 2004-04-22 2009-08-26 Dainippon Sumitomo Pharma Co Pharmazeutisches präparat mit einer bakterienzellwand-skelett-komponente
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
BR112016029581B1 (pt) 2014-06-17 2022-05-03 Crown Laboratories, Inc Propionibacterium acnes geneticamente modificada, composição e seus usos
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
CN116761582A (zh) 2020-06-23 2023-09-15 皇冠实验室有限公司 益生菌皮肤制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (de) * 1972-06-20 1973-12-27
FR2269962B1 (de) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白ｗｅｎａｃ及びその製造法
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism

Also Published As

Publication number Publication date
HU192585B (en) 1987-06-29
FI843716A0 (fi) 1984-09-21
JPS60120817A (ja) 1985-06-28
ES536167A0 (es) 1986-07-16
DE3434766A1 (de) 1986-04-30
FR2552326A1 (fr) 1985-03-29
DK446684D0 (da) 1984-09-19
CH664897A5 (de) 1988-04-15
GB2149301A (en) 1985-06-12
IN157240B (de) 1986-02-15
SE8404707D0 (sv) 1984-09-20
NO843776L (no) 1985-03-25
IL73034A (en) 1988-11-15
ES8608872A1 (es) 1986-07-16
NZ209635A (en) 1989-01-27
JPS6254775B2 (de) 1987-11-17
GB2149301B (en) 1988-06-22
DE3434766C2 (de) 1987-05-14
ZA847405B (en) 1985-05-29
KR850002404A (ko) 1985-05-13
IT1179444B (it) 1987-09-16
FR2552326B1 (fr) 1988-05-13
DK446684A (da) 1985-03-24
KR870000843B1 (ko) 1987-04-25
GB8423993D0 (en) 1984-10-31
US4663306A (en) 1987-05-05
AT385659B (de) 1988-05-10
BE900650A (fr) 1985-03-21
FI843716L (fi) 1985-03-24
AU3340084A (en) 1985-03-28
IT8448894A0 (it) 1984-09-24
AU566234B2 (en) 1987-10-15
ATA302384A (de) 1987-10-15
HUT35521A (en) 1985-07-29
SE8404707L (sv) 1985-03-24
CA1244765A (en) 1988-11-15

Similar Documents

Publication Publication Date Title
NL8402902A (nl) In pyridine oplosbaar extrakt - geraffineerd ontgift endotoxinesamenstelling en gebruik ervan.
KR870000842B1 (ko) 정제 해독된 내독소 및 그의 제조방법
US4436728A (en) Refined detoxified endotoxin product
US4435386A (en) Refined detoxified endotoxin product
US4505900A (en) Refined detoxified endotoxin product
US4877611A (en) Vaccine containing tumor antigens and adjuvants
US4505899A (en) Refined detoxified endotoxin product
JPS6254774B2 (de)

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed